Antony

ANTONY, France, November 10, 2010 - Following the announcement that Wendel had entered exclusive negotiations with Ares Life Sciences on October 28, 2010, with a view to selling its entire stake (around 46%) in Stallergenes, the company's Works Council met on November 10, 2010.

ANTONY, France, October 14, 2010 - EUR million 2009 09-Aug 2010 10-Sep EURm %Sales Var.% EURm %Sales Var.% Southern Europe(1) 26 68 9 29.2 70 12 Other EU countries(2) 10.3 27 20 10.6 25 3 Other markets 1.9 5 8 2.2 5 15 SLIT 30.5 79 16 34.7 83 14 SCIT 6.3 17 -2 5.9 14 -6 Other products 1.4 4 0 1.3 3 -8 Total Q3 sales 38.2 100 12 42 100 10 Southern Europe(1) 96.3 71 9 108.4 71 13 Other EU countries(2) 34.4 25 27 38 25 10 Other markets 5.2 4 -5 6.2 4 21 SLIT 111.6 82 14 129 85 16 SCIT 19.1 14 2 18.4 12 -4 Other products 5.2 4 7 5.2 3 -1 Cumulated sales 135.9 100 12 152.6 100 12 (1) Portugal, Spain, France, Italy, Greece; (2) Switzerland included Sales growth Consolidated sales for the 3rd quarter of 2010 grew by 10% compared to the same period last year to EUR 42.0 million, resulting in sales growth of 12% during the first 9 months of the year.

ANTONY, France, September 6, 2010 - Stallergenes S.A.

ANTONY, France, August 27, 2010 - - First Half-Year 2010 RESULTS - Excellent 1st Half-Year 2010 Performance by Stallergenes - Growth in France and Internationally +13% - Very Strong net Profit Growth +51% - Free Cash Flow Growth +90% The Board of Directors' approved the 2010 half-year financial statements at its meeting of 25 August 2010, chaired by Albert SAPORTA: 2010 half-year financial statements In EURm H1 2009 09/08 H1 2010 10/09 %CA Var.% %CA Var.% Sales 97.6 100.0 12 110.6 100.0 13 Cost of goods sold (22.5) (23.1) 13 (24.1) (21.8) 7 SG&A (37.8) (38.8) 8 (43.9) (39.7) 16 Profit before R&D 37.3 38.2 16 42.7 38.6 14 R&D costs (21.3) (21.8) 30 (16.6) (15.0) (22) R&D revenues 3.6 3.7 35 3.5 3.2 (2) EBIT 19.6 20.1 7 29.5 26.7 51 Net result, group 13.4 13.7 11 20.2 18.2 51 share Pour EBITDA 24.1 24.7 12 35.6 32.2 48 Com.

ANTONY, France, June 28, 2010 - After having announced positive results for the first year of its phase IIb/III clinical trial (VO 57.07) conducted on Actair(R) sublingual allergen immunotherapy tablets in allergic rhinitis triggered by house dust mites in April 2009, Stallergenes S.A.